FINWIRES · TerminalLIVE
FINWIRES

$XENE

10 stories mentioning XENEUpdated 2d ago

Every FINWIRES story that references XENE, newest first.

What are analysts saying about XENE?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on XENE?

Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%The iShares Biotechnology ETF (IBB) fell 1.1%.In corporate news, Eli Lilly (LLY) said Friday that the US Food and Drug Administration has approved Inluriyo in combination with Verzenio for breast cancer. Lilly shares were up 0.1%.The US Treasury Department is drafting rules that could allow pharmaceutical companies to enter into licensing agreements for Chinese drugs that do not involve pathogens or potential bio-weapons, Reuters reported. Pfizer (PFE) and other pharmaceutical companies have met with Trump administration officials in recent months to advocate against broad restrictions on investments in Chinese drug development, the report said. Pfizer shares were down 0.4%.Cooper (COO) shareholder Jana Partners is urging the company to immediately launch an external search for a new CEO, appoint a new board chair, and evaluate asset sales, it said in a letter dated Thursday. Cooper shares rose 2.8%.Xenon Pharmaceuticals (XENE) shares fell 30% after the company paused enrollment of new patients in studies for major depressive disorder and bipolar depression.

$COO$LLY$PFE$XENE
Sectors

Sector Update: Healthcare Stocks Decline Friday Afternoon

Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) fell 1.3%.In corporate news, the US Treasury Department is drafting rules that could allow pharmaceutical companies to enter into licensing agreements for Chinese drugs that do not involve pathogens or potential bio-weapons, Reuters reported. Pfizer (PFE) and other pharmaceutical companies have met with Trump administration officials in recent months to advocate against broad restrictions on investments in Chinese drug development, the report said. Pfizer shares were down 0.4%.Cooper (COO) shareholder Jana Partners is urging the company to immediately launch an external search for a new CEO, appoint a new board chair, and evaluate asset sales, it said in a letter dated Thursday. Cooper shares rose 3.5%.Xenon Pharmaceuticals (XENE) shares fell nearly 30% after the company paused enrollment of new patients in studies for major depressive disorder and bipolar depression.

$COO$PFE$XENE
Wire

Xenon Pharmaceuticals' Azetukalner Retains Core Epilepsy Value, RBC Capital Markets Says

Xenon Pharmaceuticals' (XENE) enrollment pause in an ongoing phase 3 trial of azetukalner adds risk to the experimental treatment's expansion into major depressive disorder and bipolar depression, but should not impact the main value-driving epilepsy indication, RBC Capital Markets said in a note Thursday.The investment firm said the risk/benefit in psychiatric indications had been deemed less certain given prior safety observations, while the adverse events profile in epilepsy is "cleaner" compared with other anti-seizure medications.The company has submitted a new drug application for azetukalner in focal seizures to the US Food and Drug Administration and RBC said it does not see any major risk to the filing timelines or commercial launch. Azetukalner is expected to have a strong uptake after its likely approval, according to the note.The firm said the company may still see a path forward for azetukalner in psychiatry, but the commercial opportunity is likely "a bit more diminished" and the probability of expansion into major depressive disorder and bipolar depression is now lower.RBC Capital Markets lowered its price target on the stock to $70 from $81, with a rating of outperform, speculative risk.Shares of Xenon Pharmaceuticals were down more than 29% in Friday trading.Price: $40.55, Change: $-16.80, Percent Change: -29.29%

$XENE
Commodities

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday as Tech Rally Continues

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was 0.03% lower and the actively traded Invesco QQQ Trust (QQQ) was 0.2% higher in Friday's premarket activity amid technology gains and the Federal Reserve's rate hike.US stock futures were mixed, with S&P 500 Index futures up 0.1%, Dow Jones Industrial Average futures slipping 0.03%, and Nasdaq futures gaining 0.4% before the start of regular trading.State unemployment and leading indicators data for August are due to be released at 10 am ET.Federal Reserve Vice Chair for Supervision Michelle Bowman and Kansas City Fed President Jeffrey Schmid are slated to speak Friday.In premarket activity, bitcoin was up by 1.9%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 2% higher, Ether ETF (EETH) advanced 2.6%, and Bitcoin & Ether Market Cap Weight ETF (BETH) advanced 0.5%.Power Play:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated 0.2%, the Vanguard Health Care Index Fund (VHT) was 0.2% lower, while the iShares US Healthcare ETF (IYH) gained 1%. The iShares Biotechnology ETF (IBB) was down 0.1%.Xenon Pharmaceuticals (XENE) shares were down 22% after the company paused enrollment of new patients in studies for major depressive disorder and bipolar depression.Winners and Losers:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was flat, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was down 0.2%, and the iShares US Consumer Staples ETF (IYK) was flat. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained 0.2%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was flat.CAVA (CAVA) shares were up more than 3% pre-bell after the company said its board authorized a plan for the repurchase of up to $100 million of its outstanding common stock.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced 0.1%, the iShares US Technology ETF (IYW) was 0.8% higher, and the iShares Expanded Tech Sector ETF (IGM) was up 0.3%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) gained 0.6%, while the iShares Semiconductor ETF (SOXX) rose by 0.2%.Alphabet (GOOG, GOOGL) shares were up 2% in premarket activity after the company said its Waymo unit intends to open its fully autonomous ride-hailing service to riders in Singapore in 2028.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated 0.4%. Direxion Daily Financial Bull 3X Shares (FAS) was down 0.9%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 1.3% higher.HSBC (HSBC) shares were down 1% after the Australian reported that National Australia Bank is considering the acquisition of HSBC's Australian retail deposit business.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.01%, while the Vanguard Industrials Index Fund (VIS) and the iShares US Industrials ETF (IYJ) were flat.Waste Connections (WCN) stock was up more than 1% before the opening bell after UBS upgraded it to buy from neutral.EnergyThe iShares US Energy ETF (IYE) was down 0.3%, while the State Street Energy Select Sector SPDR ETF (XLE) was 0.6% lower.BP (BP) stock was down more than 1% after Osaka Gas said BP Developments Australia has agreed to sell a 5% stake in the Browse liquefied natural gas project in Western Australia to Osaka Gas Browse.CommoditiesFront-month US West Texas Intermediate crude oil gained by 0.2% to reach $102.12 per barrel on the New York Mercantile Exchange. Natural gas was up 0.3% at $2.91 per 1 million British Thermal Units. The United States Oil Fund (USO) increased by 0.2%, while the United States Natural Gas Fund (UNG) was 0.4% higher.Gold futures for November retreated by 0.04% to $4,397.80 an ounce on the Comex. Silver futures rose 1.1% to $66.83 an ounce. SPDR Gold Shares (GLD) was up by 0.6%, and the iShares Silver Trust (SLV) rose by 2%.

Dow JonesNasdaq CompositeS&P 500$BP$CAVA$FAS$FAZ$GLD$GOOG$GOOGL$HSBC$IBB$IGM$IYE$IYH$IYJ$IYK$IYW$QQQ$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$WCN$XENE$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Healthcare Stocks Flat to Lower Pre-Bell Friday

Healthcare stocks were flat to lower pre-bell Friday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.Xenon Pharmaceuticals (XENE) shares were down more than 23% after the company voluntarily paused enrollment of new patients in studies for major depressive disorder and bipolar depression.AstraZeneca (AZN) and Daiichi Sankyo's Enhertu has been recommended for approval in the European Union as a monotherapy for the adjuvant treatment of adults with resected HER2 positive breast cancer who have residual disease after neoadjuvant treatment, Daiichi Sankyo said. AstraZeneca stock was 0.7% higher premarket.Merck's (MRK) Keytruda in combination with Padcev as a treatment for adults with resectable muscle-invasive bladder cancer was granted a positive opinion recommending approval by the European Medicines Agency's Committee for Medicinal Products for Human Use, the company said. Merck stock was down 0.4% pre-bell.

$AZN$IBB$MRK$XENE$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were flat to lower pre-bell Friday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.Xenon Pharmaceuticals (XENE) shares were down more than 23% after the company voluntarily paused enrollment of new patients in studies for major depressive disorder and bipolar depression.

$XENE
Research

Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold From Buy, Adjusts PT to $46 From $90

Xenon Pharmaceuticals (XENE) has an average rating of buy and mean price target of $77.06, according to analysts polled by FactSet.

$XENE
Insider Trading

Xenon Pharmaceuticals Insider Sold Shares Worth $640,550, According to a Recent SEC Filing

Steven Gannon, Director, on August 11, 2026, sold 10,000 shares in Xenon Pharmaceuticals (XENE) for $640,550. Following the Form 4 filing with the SEC, Gannon has control over a total of 1,870 common shares of the company, with 1,870 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1582313/000119312526349351/xslF345X05/ownership.xml

$XENE
Wire

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

Xenon Pharmaceuticals' (XENE) recent pre-NDA meeting with the FDA for azetukalner appeared constructive, supporting the drug's planned Q3 new drug application filing and potential 2027 launch, RBC Capital Markets said.The investment firm said in a Thursday note that azetukalner, Xenon's investigational treatment for focal onset seizures, remains on track for submission later this quarter. It added that the FDA appeared receptive to including all four doses on the drug's label.RBC said payer engagement has been encouraging, with potential for azetukalner to command a premium to Xcopri pricing given its novel mechanism of action, efficacy profile, lack of titration requirements, minimal drug-drug interactions and favorable tolerability.The investment firm also cited early-stage pain program data showing plasma and cerebrospinal fluid concentrations above predicted therapeutic exposures for Xenon's investigational candidates, though it said the safety profile remains unclear pending completion and full unblinding of the phase 1 studies.RBC lowered its price target on Xenon Pharmaceuticals to $81 from $82 while reiterating its outperform rating.Price: $63.35, Change: $-1.20, Percent Change: -1.86%

$XENE
Wire

Wedbush Adjusts PTon Xenon Pharmaceuticals to $71 From $63, Maintains Outperform Rating

Xenon Pharmaceuticals (XENE) has an average rating of buy and mean price target of $80.74, according to analysts polled by FactSet.Price: $63.62, Change: $-0.93, Percent Change: -1.44%

$XENE

Track with the FINWIRES app suite